Cardiology General Medicine
RIETE Score for Bleeding Risk in VTE
Predicts risk of major bleeding during first 3 months of anticoagulation for VTE.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE · Venous Thromboembolism
- Wells Criteria for PE · Venous Thromboembolism
- Wells Criteria for DVT · Venous Thromboembolism
- PERC Rule for PE · Venous Thromboembolism
- Revised Geneva Score for PE · Venous Thromboembolism
- Wells DVT Score · Venous Thromboembolism
Drugs
- Rivaroxaban (PE Treatment) · Venous Thromboembolism
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Vasopressin / Terlipressin · Vasopressin Analogue — Vasodilatory Shock / Variceal Bleeding
- Bivalirudin · Anticoagulation
- Tranexamic Acid (Heavy Menstrual Bleeding) · Antifibrinolytic (Gynaecological Use)
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.